B+
Bull case
25%
Probability
Target price
$280.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
CAH
Cardinal HealthBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$250.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$205.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+70.5
Score
AI commentary
Post-earnings tone is mildly constructive: the company delivered strong EPS growth and above-long-term FY27 guidance, while an Investor's Business Daily headline said the shares ticked higher despite a mixed quarter. The exact post-release price move is unavailable, and the packet contains no post-print analyst revisions or target changes, so this remains a constructive monitoring view rather than a high-conviction bullish signal.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-11eventFY26 mixed earnings outcome with FY27 EPS guide resetMedium impact
The official release reported Q4 FY26 revenue of $63.7 billion and non-GAAP diluted EPS of $2.91. Against the packet's preprint Zacks estimates of $65.61 billion revenue and $2.42 EPS, this indicates a mixed top-line/EPS result; Cardinal Health then guided FY27 non-GAAP EPS to $12.40-$12.60, representing 13%-15% growth and exceeding its long-term framework [#SEC-8K-2026-08-11].
2026-08-14catalystPost-print digestion of mixed revenue qualityMedium impact
Investors must weigh the Q4 earnings outcome against revenue growth of 6% and a $100 million one-time IEEPA tariff-refund benefit included in non-GAAP earnings. Near-term sentiment may remain sensitive to how much of the FY27 outlook is recurring versus benefit-driven [#SEC-8K-2026-08-11].
2027-08-14catalystBroad-based profit execution and capital returnsHigh impact
FY26 profit growth extended across all five operating segments, with $5.2 billion of operating cash flow, $5.0 billion of adjusted free cash flow, $1.4 billion of repurchases, and a new $5.0 billion authorization. Sustaining this execution is the main longer-term upside case [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology